Format

Send to

Choose Destination
Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Author information

1
Department of Hematology AZ St-Jan Brugge-Oostende, Belgium.
2
EORTC Headquarters, Brussels, Belgium.
3
Hematology, Sapienza University, Rome, Italy.
4
Department of Hematology, Radboud University, Medical Center, Nijmegen, the Netherlands.
5
Department of Hematology, Leiden University Medical Center, the Netherlands.
6
Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
7
Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy.
8
Jeroen Bosch Medical Center, Den Bosch, the Netherlands.
9
Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Rome, Italy.
10
Department of Hematology, Hôpital Saint-Antoine, APHP, Paris, France.
11
Department of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium.
12
Department of Tumorimmunology, Radboud University, Medical Center, Nijmegen, the Netherlands.
13
GIGA-I3-Hematology, University of Liège, Belgium f.baron@ulg.ac.be.
PMID:
27789677
PMCID:
PMC5286953
DOI:
10.3324/haematol.2016.153130
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center